Cabazitaxel for castration-resistant prostate cancer

Lancet. 2011 Jan 8;377(9760):121; author reply 122-3. doi: 10.1016/S0140-6736(11)60012-3.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Androgen Antagonists / administration & dosage*
  • Androgen Antagonists / adverse effects*
  • Antineoplastic Agents, Hormonal / administration & dosage*
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Drug Administration Schedule
  • Drug Resistance, Neoplasm*
  • Humans
  • Male
  • Mitoxantrone / administration & dosage
  • Mitoxantrone / adverse effects
  • Prednisone / administration & dosage
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / immunology
  • Stroke Volume / drug effects
  • Taxoids / administration & dosage*
  • Taxoids / adverse effects*
  • Treatment Failure
  • Treatment Outcome

Substances

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Taxoids
  • cabazitaxel
  • Mitoxantrone
  • Prednisone